CIK 0001175680 · Non-accelerated filer<br>Smaller reporting company
CytoDyn Inc.
Sign in to watch- Ticker
- CYDY
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- May 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 753056237
- Phone
- 360-980-8524
- Business address
- 1111 MAIN STREET, SUITE 660, VANCOUVER, WA, 98660
- Former names
- CYTODYN INC, REXRAY CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-09-15 | Kelly Scott A. CMO | Grant or award | +9,457 | 2,101,312 | ||
| 2022-09-15 | Migliarese Antonio CFO | Grant or award | +7,086 | 127,562 | ||
| 2022-09-15 | Ray Nitya G. Chief Technology Officer | Grant or award | +8,965 | 444,887 | ||
| 2022-09-06 | Brunke Karen J Director | Grant or award · Non-qualified stock option (right to buy) | +37,500 | 37,500 | ||
| 2022-09-06 | Brunke Karen J Director | Grant or award · Non-qualified stock option (right to buy) | +247,111 | 247,111 | ||
| 2022-09-06 | Ndhlovu Lishomwa C Director | Grant or award · Non-qualified stock option (right to buy) | +112,500 | 112,500 | ||
| 2022-09-06 | Ndhlovu Lishomwa C Director | Grant or award · Non-qualified stock option (right to buy) | +50,000 | 50,000 | ||
| 2022-09-06 | Ndhlovu Lishomwa C Director | Grant or award · Non-qualified stock option (right to buy) | +247,111 | 247,111 | ||
| 2022-09-06 | Dunlap Ryan Director | Grant or award · Non-qualified stock option (right to buy) | +185,333 | 185,333 | ||
| 2022-09-06 | Urbach Tanya Durkee Director | Grant or award · Non-qualified stock option (right to buy) | +112,500 | 112,500 | ||
| 2022-09-06 | Urbach Tanya Durkee Director | Grant or award · Non-qualified stock option (right to buy) | +247,111 | 241,111 | ||
| 2022-08-31 | Migliarese Antonio CFO | Grant or award | +8,313 | 120,476 | ||
| 2022-08-31 | Kelly Scott A. CMO | Grant or award | +11,094 | 2,091,855 | ||
| 2022-08-31 | Ray Nitya G. Chief Technology Officer | Grant or award | +10,516 | 435,922 | ||
| 2022-08-15 | Ray Nitya G. Chief Technology Officer | Grant or award | +6,588 | 425,406 | ||
| 2022-08-15 | Kelly Scott A. CMO | Grant or award | +6,950 | 2,080,761 | ||
| 2022-08-15 | Migliarese Antonio CFO | Grant or award | +5,208 | 112,163 | ||
| 2022-07-31 | Ray Nitya G. Chief Technology Officer | Grant or award | +7,102 | 418,818 | ||
| 2022-07-31 | Migliarese Antonio CFO & Interim President | Grant or award | +5,614 | 106,955 | ||
| 2022-07-31 | Kelly Scott A. CMO | Grant or award | +7,492 | 2,073,811 |
Page 4 of 33 · 652 trades